PD780 - PHARMACIST-LED CDTM SCREENING ENABLES EARLY MULTIDISCIPLINARY INTERVENTION FOR CANCER CACHEXIA AND IMPROVES PHYSICAL FUNCTION IN DIGESTIVE CANCERS

PD780

PHARMACIST-LED CDTM SCREENING ENABLES EARLY MULTIDISCIPLINARY INTERVENTION FOR CANCER CACHEXIA AND IMPROVES PHYSICAL FUNCTION IN DIGESTIVE CANCERS

Y. Aimono^1,*, T. Yagisawa¹, E. Ogawa¹, T. Iwayama¹, W. Satou¹, N. Abe², S. Kikuchi³, T. Kamoshida⁴

¹Pharmacy, ²Dietetics, ³Nurse, ⁴Gastroenterology, Hitachi General Hospital, Hitachi, Japan

Rationale: Anamorelin, a ghrelin receptor agonist approved only in Japan, allows evaluation of real-world cachexia care. We assessed whether a pharmacist-led Collaborative Drug Therapy Management (CDTM) system improves outcomes of multimodal intervention and examined gaps between Japanese and Asian diagnostic criteria.

Methods: From Dec 2021 to June 2025, cancer patients were screened via a two-step CDTM protocol (nurse-led weight-loss screening, then pharmacist-led assessment). Eligible patients (n=22) received anamorelin with nutritional and exercise counseling. Physical function was assessed at 12 weeks via gait speed, 30-second chair stand test (CS-30), and Clinical Frailty Scale (CFS).

Results:  Of 311 screened patients, 68 (21.9%) met weight-loss criteria, but only 18 (5.8%) fulfilled strict Japanese eligibility. In the intervention group (n=22), significant improvements occurred in CS-30 15.11±21.55%（p=0.006）, gait speed 11.95±17.52%(p=0.005）, and -2.27±1.55(p<0.01）. No significant changes were observed in handgrip strength or lean body mass. No Grade ≥3 adverse events occurred.

Conclusion: Pharmacist-led CDTM significantly improved physical function, showing that functional improvement may precede muscle mass gains. Discrepancies between Japanese criteria and 2023 AWGS standards suggest current indications may delay supportive care. This model supports earlier, scalable cachexia management in Asian oncology.

Disclosure of Interest: None declared